Martin Widschwendter

Martin Widschwendter

London, United Kingdom
Department of Women's Cancer, EGA Institute for Women's Health, Faculty of Population Health Sciences, University College London
UCL Head of Department of Women's Cancer and UCLH Consultant Gynaecological Oncology Surgeon

Prof Martin Widschwendter MD, FRCOG is Professor in Women's Cancer, Dept. of Women’s Cancer Head, University College London (UCL) and Consultant Gynaecological Oncology Surgeon, University College London Hospital (UCLH). In 2001, having completed his training in Gynaecology & Obstetrics in Austria, Martin worked at the Norris Comprehensive Cancer Centre, LA, USA and spent 3 years as lead clinician/surgeon of a large breast cancer centre before embarking on a career at UCL/UCLH from 2005 where he undertook sub-speciality training in gynae onc. As the Head of Department of Women’s Cancer, EGA Institute for Women's Health, UCL, he established his research group focusing on the role of early detection, risk prediction and prevention of breast and gynaecological cancers. Martin is an author on > 155 papers in high impact journals, has contributed to numerous text books and secured more than £17M of grant income in the last 10 years. His work has been quoted > 11,000 times and his current H-Index is 51. He has lectured widely on his research and clinical experience in the UK and abroad. Martin leads on 3 major research programmes: H2020 FORECEE (Female cancer predictiOn using ceRvical cEll omiCs to individualisE prevention) aims to develop individual risk predictors for cancers that are hormone-associated and specific to women (breast, ovarian, endometrial and cervical cancers); BRCA PROTECT (BRCA1/2: PReventiOn of breasT and sErous pelviC cancers via sysTems medicine) aims to understand the molecular events that lead to the development of breast and ovarian cancer, so that effective prediction and ultimately prevention of the occurrence of these cancers can take place; and the European Research Council (ERC) Advanced Grant BRCA-ERC (Understanding cancer development in BRCA 1/2 mutation carriers for improved Early detection and Risk Control)–supporting BRCA PROTECT & BRCA PREVENT. Martin’s particular clinical interest is in complex radical laparoscopic and open surgery.